Why the study?
Atherosclerosis forms the pathological basis of most cardiovascular and cerebrovascular diseases, motivating a review of CTRP1's role in atherogenesis and its potential as a novel biomarker and therapeutic target.
Design
Review
Answers are grounded in this paper and cite their sources.
CTRP1 merits evaluation as biomarker and target in atherosclerosis; leaves open clinical translation from current evidence.
Atherosclerosis serves as the pathological basis of most cardiovascular and cerebrovascular diseases. C1q tumor necrosis factor-related protein 1 (CTRP1) is a 35-kDa glycoprotein synthesized by various tissues and cells, such as adipose tissue and macrophages. As an adiponectin paralog, CTRP1 signals through adiponectin receptor 1 and participates in a variety of pathophysiological processes. Circulating CTRP1 levels are significantly increased in patients with coronary artery disease. Importantly, CTRP1 was shown to accelerate the development of atherosclerosis by promoting vascular inflammation, macrophage foam cell formation, and endothelial barrier dysfunction. This review focused on recent advances regarding the role of CTRP1 in atherogenesis with an emphasis on its potential as a novel biomarker and a promising therapeutic target for atherosclerosis-related diseases.
No takes yet. Share an insight, caveat, or question.
Yin et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: